Resources Management Corp CT ADV Reduces Stock Holdings in Danaher Corporation $DHR

Key Points

• Resources Management Corp CT ADV has reduced its stake in Danaher Corporation by 2.7%, selling 1,274 shares to hold a total of 45,197 shares valued at approximately $9.27 million.
• In the first quarter, several institutional investors, including GHP Investment Advisors Inc. and Dunhill Financial LLC, significantly increased their positions in Danaher.
• Danaher reported better-than-expected quarterly earnings with an EPS of $1.80, surpassing analysts' estimates of $1.64, and has a consensus rating of "Moderate Buy" among investment analysts.

Resources Management Corp CT ADV lowered its stake in Danaher Corporation (NYSE:DHR - Free Report) by 2.7% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 45,197 shares of the conglomerate's stock after selling 1,274 shares during the quarter. Danaher makes up about 1.3% of Resources Management Corp CT ADV's holdings, making the stock its 19th biggest position. Resources Management Corp CT ADV's holdings in Danaher were worth $9,265,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of DHR. Heck Capital Advisors LLC purchased a new stake in shares of Danaher in the fourth quarter valued at $27,000. GHP Investment Advisors Inc. lifted its holdings in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher during the 1st quarter worth about $31,000. Finally, Dunhill Financial LLC grew its holdings in shares of Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after buying an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Trading Down 2.2%

NYSE:DHR traded down $4.39 on Tuesday, hitting $194.24. 3,344,891 shares of the stock were exchanged, compared to its average volume of 2,899,976. The stock has a fifty day moving average of $201.82 and a 200-day moving average of $199.20. The stock has a market cap of $139.09 billion, a PE ratio of 41.33, a PEG ratio of 2.77 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

Insider Activity

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Wells Fargo & Company reduced their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Royal Bank Of Canada set a $241.00 price objective on Danaher in a report on Tuesday, September 2nd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a research note on Friday, July 11th. Finally, Guggenheim reiterated a "buy" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $246.35.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.